Abstract. The dysregulation of microRNAs (miRNAs) is associated with the development and progression of a variety of cancers, including liver cancer. Aberrant expression of miRNA (miR)-124 has been demonstrated in liver cancer, but its functional mechanism in liver cancer is still largely unknown. Metastasis of liver cancer is one of the most common causes of mortality. The present study showed that miR-124 inhibited the proliferation, migration and invasion of liver cancer cells. Furthermore, chloride intracellular channel 1 (CLIC1) was identified as a novel target of miR-124 in liver cancer cells. Overexpression of miR-124 reduced CLIC1 expression at both the protein and mRNA levels in liver cancer cells. Downregulation of CLIC1 decreased the migration and invasion of liver cancer cells without affecting cell proliferation. Taken together, these results showed that CLIC1 is a critical target for miR-124-mediated inhibitory effects on cell migration and invasion. Thus, miR-124 or suppression of CLIC1 may have diagnostic value and therapeutic potential for the treatment of human liver cancer.
Introduction
Liver cancer is the fifth most frequently diagnosed cancer and the second most common cause of cancer mortality in males worldwide (1) . In females, the numbers are as high as ninth and sixth worldwide for diagnosed cancer and cause of mortality, respectively (1) . Liver cancer constitutes a major global health problem, with the highest incidence rates in East Asia (1) . The major causes of liver cancer include chronic hepatitis B and C virus infection, aflatoxin exposure, alcohol abuse, smoking and obesity (2) . Most liver cancer patients are diagnosed at advanced stages with a poor prognosis; surgical resection and chemotherapy may prolong the overall survival time of liver cancer patients (3) . Therefore, there is an urgent need to identify effective biomarkers and therapeutic targets for the treatment of liver cancer.
MicroRNAs (miRNAs) are small noncoding RNAs composed of ~22 nt. They usually bind to the 3'-untranslated region (UTR) of mRNAs and suppress gene expression by either degrading the mRNA or suppressing mRNA translation into protein, depending on pairing complementarity (4, 5) . Growing evidence indicates that miRNAs play important roles in many biological processes, including development, proliferation, differentiation, apoptosis and oncogenesis (5) . It has been shown that miRNAs are abnormally expressed in hepatocellular carcinoma (HCC), one of the most common primary liver cancers representing 75-85% of cases (1) , and act as tumor oncogenes or suppressors by affecting various targets to regulate tumorigenesis, invasion and metastasis (6) . Furthermore, many miRNAs show promise as prognostic markers or therapeutic targets for the treatment of different cancer types (7, 8) .
miRNA-124 (miR-124) was first identified to be highly expressed in the central nervous system, and it regulates many neuronal activities (9) (10) (11) . Subsequent studies revealed that miR-124 is significantly downregulated in several types of human cancer and functions as a tumor suppressor (9, 12, 13) . miR-124 is able to recognize cell proliferation-related genes such as EPH receptor A2 (14) , Smad4 (15) , and AKT-solute carrier family 2 member 1/HKII (16) . Several studies have shown aberrant expression of miR-124 in liver cancer, and decreased expression of miR-124 is correlated with shorter overall survival and poor prognosis in patients with liver MicroRNA-124 negatively regulates chloride intracellular channel 1 to suppress the migration and invasion of liver cancer cells cancer, suggesting that miR-124 might be a potential biomarker for the early diagnosis of liver cancer (17, 18 (24) . All of these findings suggest that CLIC1 is an oncogene or a tumor marker in the progression of cancer. The present study identified CLIC1 as a miR-124 target gene by mass-spectrometry, luciferase assay and western blot analysis. Using further knockdown and functional assays, it was confirmed that miR-124 functions as a tumor suppressor through the downregulation of CLIC1. Thus, miR-124 and CLIC1 may serve as a biomarkers or have therapeutic potential for the treatment of human liver cancer. Plasmid construction. Total RNA was extracted from HepG2 cells using TRIzol ® reagent (Thermo Fisher Scientific, Inc.) and was reverse-transcribed using a murine Moloney Leukemia Virus (M-MLV) kit (Takara Biotechnology Co., Ltd.). The PCR was performed using Ex Taq (Takara Biotechnology Co., Ltd.). The 3'-UTR of CLIC1 was amplified by PCR and constructed into the SpeI/HindIII sites downstream of the luciferase gene in the pMIR-REPORT Luciferase miRNA Expression Reporter Vector (Ambion; Thermo Fisher Scientific, Inc.). The primers for the 3'-UTR of CLIC1 were as follows: Forward, 5'-gac tag tGC CCC TCC TGG GAC TCC CT-3' and reverse primer, 5'-atg caa gct tTT TTG CGT AAA AAC ACT TG-3'. A CLIC1 expression vector, pEGFP-N1-CLIC1, was constructed in our laboratory. Primers for CLIC1 mRNA were as follows: Forward, 5'-atc gct cga gAT GGC TGA AGA ACA ACC GCA GG-3' and reverse, 5'-agt cga cTT ATT TGA GGG CCT TTG CCA C-3'. The PCR reaction was carried out under the following conditions: 95˚C for 5 min; 30 cycles of 95˚C for 30 sec, 56˚C for 30 sec and 72˚C for 1 min; and 72˚C for 5 min. All constructs were confirmed by SpeI/HindIII or XhoI/BamHI restriction digestion and DNA sequencing. The restriction digestion was performed at 37˚C for 1 h and the DNA sequencing was performed by BGI.
Materials and methods

Hepatic
CLIC1 knockdown. CLIC1 small interfering RNA (siR-CLIC1) and scramble siRNA control (siR-NC) was purchased from Shanghai GeneChem Co., Ltd. The siR-CLIC1 sequence was 5'-GGA CCG AGA CAG TGC AGA A-3' and the siR-NC sequence was 5'-TTC TCC GAA CGT GTC ACG T-3'. HepG2 cells were seeded 80% confluent and transfected with 50 nm siRNA using Lipofectamine ® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). The knockdown effect was evaluated by reverse transcription-quantitative PCR (RT-qPCR) and western blotting at 24, 48 and 72 h post-transfection.
RT-qPCR.
Total RNA from HepG2 and HL-7702 cells was extracted with TRIzol ® reagent (Invitrogen; Thermo Fisher Scientific, Inc.). The expression of miR-124 was measured using a TaqMan MicroRNA assay kit (Ambion; Thermo Fisher Scientific, Inc.), according to the manufacturer's instructions (25) . Relative expression was calculated using the 2 -ΔΔCq method and normalized to the expression of RNU6B (Ambion; Thermo Fisher Scientific, Inc.) (26) . For the CLIC1 mRNA analysis, the total RNA was extracted from cells transfected with miR-124 or control with TRIzol ® reagent. cDNA was synthesized using a M-MLV (Takara Biotechnology, Co., Ltd.) under the following program: 70˚C for 10 min, then cooling on ice, 42˚C for 1 h, 70˚C for 15 min and held at 4˚C. qPCR was performed in triplicate in a 20 µl reaction volume with SYBR-Green (Bio-Rad Laboratories, Inc.) as follows: 95˚C for 3 min; and 40 cycles of 95˚C for 20 sec, 58˚C for 30 sec and 72˚C for 20 sec. The primers used for RT-qPCR were as follows: CLIC1 forward, 5'-AAT TCA AAC CCA GCA CTC AAT G-3' and reverse primer, 5'-CAG CAC TGG TTT CAT CCA CTT-3'; and GAPDH forward, 5'-CCA CTC CTC CAC CTT TGA C-3' and reverse primer, 5'-ACC CTG TTG CTG TAG CCA-3' . The expression level of GAPDH was used as a control. Relative expression was calculated via the comparative Cq method. The specificity of the PCR products was confirmed by melting curve analysis.
Immunoblotting. Total protein was isolated from cell lines transfected with RNA oligonucleotide and/or plasmid DNA in cell lysis buffer [50 mM Tris-HCl (pH 7.5), 150 mm NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM PMSF and 1% sodium deoxycholate]. Protein concentration was measured using a Bio-Rad protein assay kit (cat. no. 5000002; Bio-Rad Laboratories, Inc.). Protein samples were separated by 10% SDS-PAGE and transferred to a polyvinylidene difluoride membrane (Amersham; GE Healthcare). Primary antibody against CLIC1 (1:1,000; Santa Cruz Biotechnology, Inc.; cat. no. sc-81873) and tubulin (1:5,000; Santa Cruz Biotechnology, Inc.; cat. no. sc-365791) was applied after blocking the membrane with 5% nonfat milk in PBS + 0.1% Tween-20, at room temperature for 1 h, followed by the appropriate horseradish peroxidase-conjugated secondary antibody (1:5,000; Santa Cruz Biotechnology, Inc.; cat. no. sc-516102). The membranes were detected using an ECL western blotting detection system (EMD Millipore). Signals were calculated using ImageJ 1.50 (National Institutes of Health).
Proteomic analysis. HepG2 cells were transfected with miR-124 or pre-scrambled miRNA control (NC). After 48 h of transfection, cellular proteins were extracted using the ProteoPrep Total Extraction Sample kit (Sigma-Aldrich; Merck KGaA) and the protein concentration was determined by Bio-Rad Protein Assay (Bio-Rad Laboratories, Inc.). Proteins were used for two-dimensional gel electrophoresis (2-DGE) as described in the manufacturer's instructions (Bio-Rad Laboratories, Inc.). The first-dimension isoelectric-focusing of 2-DGE was carried out using pH 3-10 immobilized pH gradient ReadyStrips, and in the second dimension, the protein was separated by 8-14% gradient SDS-PAGE. The gels were stained with Coomassie brilliant blue and scanned with a flatbed scanner. The analysis included picture merge and protein spot detection performed by PDQuest 2-DE analysis software (BioRad Laboratories, Inc., version 8.0). Gel comparison was performed using the 'Automated Detection and Matching' function in PDQuest software, combined with manual pair correction. The yellow-labeled spots showed at least a 2-fold decrease between the miR-124 sample and control, with statistical significance (P<0.05). Selected protein spots were excised from the gels and identified by mass spectrometry. Mass spectrometry analysis was performed at the Teaching Center of Biology Experiment, School of Life Sciences, Sun Yat-Sen University.
Luciferase assay. HepG2 cells with 80% confluence were transfected with luciferase constructs containing the 3'-UTR of CLIC1 (2 µg) and/or miR-124 or pre-scrambled miRNA control (NC) (100 nm) using Lipofectamine ® 2000. After 48 h of transfection, cells were harvested for luciferase assays using the Luciferase Assay System (Promega Corporation), according to the manufacturer's protocol. pMIR-REPORT-β-gal was used for normalization. TargetScan (targetscan.org) was used to search for complementary sites of miR-124 in the 3'-UTR of CLIC1 mRNA.
Cell growth and viability. Cells were counted and plated at a density of 3x10 3 cells/well in 96-well plates in triplicate. Cell viability was determined at 24, 48 and 72 h post-transfection. Spectrophotometry was performed at λ=450 nm and λ ref =630 nm after incubation with 10 µl water-soluble tetrazolium salt (WST)-1 in 100 µl medium (Roche Molecular Diagnostics) for 2 h. For the colony formation assays, cells were seeded in a 6-well plate (0.8x10 3 cells/well) and cultured for 2 weeks. Colonies were fixed with cooled methanol for 10 min at 4˚C and stained using 0.1% crystal violet for 10 min at room temperature. The images were taken using a camera. Visible colonies were manually counted. Each group was measured in triplicate.
Scratch wound-healing motility assays. A total of 1.0x10 6 cells were seeded and grown to confluence in 60-mm dishes with 10% FBS DMEM media. A scratch was made on the cell monolayer using a pipette tip at 48 h after miR-124 or pre-scrambled miRNA control transfection. The cells was washed in PBS twice and cultured in DMEM without FBS. The wound areas were imaged at 24 and 48 h after the scratch was made. The distance between the two edges of the scratch was measured using the ImageJ 1.50 (National Institutes of Health). The images were taken with a Leica Microsystems, Inc. light microscope at a magnification of x100.
Transwell assay. Cell migration was detected using a 6-well plate Transwell system without Matrigel coating (BD Biosciences). Cell invasion assays were performed using Matrigel Invasion Chambers (BD Biosciences) precoated with ECM gel (Sigma-Aldrich; Merck KGaA). A total of 1.0x10 6 cells at 48 h post-transfection were seeded into the upper chamber with serum-free medium. The lower chamber was prepared with medium containing 10% FBS, which served as a chemoattractant. After incubating for 24 h, the non-invasive cells were mechanically removed. The invasive cells on the lower surface of the membrane were then washed, fixed with methanol for 20 min at 4˚C and stained with 0.1% crystal violet for 10 min at room temperature. Cells were counted in 10 random optical fields under a Leica Miscrosystems, Inc. light microscope at x400 magnification. The images were taken by a Leica Miscrosystems, Inc. light microscope at a magnification of x100.
Statistical analysis. Statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software, Inc.). All numerical data are displayed as the mean ± SEM. Statistical comparisons among two or more groups were conducted using one-way ANOVA test followed by the Newman-Keuls multiple comparison test, or Student's t-test. P<0.05 was considered to indicate a statistically significant difference.
Results
miR-124 functions as a tumor suppressor in liver cancer cells.
miR-124 levels were compared between a human liver cancer cell line and a normal liver epithelial cell line using RT-qPCR. In HepG2 liver cancer cells, the expression of miR-124 was significantly decreased compared with that in the normal liver epithelial cells (Fig. 1A) , suggesting that miR-124 may function as a tumor suppressor in liver cancer cells.
To further confirm the function of miR-124 in liver cancer cells, HepG2 cells with low miR-124 expression were used as a cell model, and miR-124 was overexpressed in HepG2 cells by transfecting miR-124 precursor; scrambled miRNA precursor was used as the NC. The increased level of miR-124 was confirmed by RT-qPCR (Fig. 1B) . Overexpression of miR-124 significantly inhibited the viability and proliferation of HepG2 cells (Fig. 1C and D) . In the scratch wound-healing motility assay, transfecting miR-124 into HepG2 cells resulted in slower closure of the wound compared with that in control cells (Fig. 1E) . In the Transwell assay without Matrigel coating, HepG2 cells expressing miR-124 migrated to a lesser extent to the lower chamber, compared with the control cells (Fig. 1F) . Similarly, cell invasion was also largely inhibited by transfecting miR-124, as demonstrated by the Transwell assay with Matrigel (Fig. 1G ). All these observations suggested that miR-124 functions as a tumor suppressor in liver cancer.
miR-124 targets CLIC1 and negatively regulates its expression.
To explore the targets of miR-124 in liver cancer cells, mass spectrometry was used to analyze the differential expression of proteins between miR-124-overexpressing HepG2 cells and control cells (Fig. 2A) . Among the proteins detected by two-dimensional gel electrophoresis, CLIC1 expression was decreased in miR-124-overexpressing cells, as compared with control cells (Fig. 2A) , suggesting that CLIC1 is one of the potential targets of miR-124. To confirm this finding, HepG2 cells were further transfected with either miR-124 or NC, and the endogenous expression of CLIC1 was detected at both the protein and mRNA levels. Overexpression of miR-124 caused a significant decrease in CLIC1 protein expression (Fig. 2B) . miRNAs are able to regulate gene expression by either degrading the mRNA of a target gene or preventing its translation. To better understand the mechanism underlying the downregulation of CLIC1 by miR-124, the mRNA level of CLIC1 was examined in miR-124-overexpressing cells. The RT-qPCR results revealed that the mRNA level of CLIC1 was reduced at 48 h after transfection with miR-124, compared with the NC (Fig. 2C) . These data indicated that CLIC1 is a target gene of miR-124, which is likely to downregulate CLIC1 through mRNA degradation.
miR-124 targets the 3'-UTR of CLIC1 mRNA.
To further identify the target region of CLIC1 for miR-124, the 3'-UTR of CLIC1 mRNA was cloned into a luciferase vector (Fig. 2D) . Co-transfection of miR-124 significantly inhibited the luciferase activity of the CLIC1 3'-UTR construct (Fig. 2E) , suggesting that miR-124 targets the 3'-UTR of CLIC1 mRNA and prevents subsequent translation. Usually, the regulatory effect of miRNAs on target genes depends on the seed region of the miRNA. Bioinformatics analysis using TargetScan was used to search for complementary sites in the 3'-UTR of CLIC1 mRNA for the seed region of miR-124 (data not shown). Unexpectedly, there is no complementary site in the 3'-UTR of CLIC1 for the seed region of miR-124.
Inhibition of cancer progression in liver cancer cells by CLIC1 knockdown.
To explore the function of CLIC1 in liver cancer, CLIC1 protein and mRNA levels were measured in a liver cancer cell line (HepG2) and in the normal human hepatocyte cell line HL-7702. Both the protein and mRNA of CLIC1 were highly expressed in HepG2 liver cancer cells, but not in the normal hepatocyte cells (Fig. 3A and B) . To confirm that miR-124 functions as a tumor suppressor by downregulating CLIC1, the effect of silencing CLIC1 was assessed in liver cancer cells. As shown in Fig. 3C and D, transfecting CLIC1 siRNA caused significant downregulation of CLIC1 protein and mRNA levels in HepG2 cells compared with control (NC). The CLIC1-deficient cells exhibited a growth rate similar to that of control cells in WST-1 and colony formation assays ( Fig. 3E and F) , suggesting that CLIC1 had no effects on the viability and proliferation of liver cancer cells. In the scratch wound-healing motility assay, CLIC1-deficient cells showed significantly slower closure of the wound than the control cells (Fig. 3G) . In the Transwell assays without Matrigel coating, fewer CLIC1-deficient cells were able to migrate through pores in the membrane to the lower chamber compared with control cells transfected with scramble siRNA (Fig. 3H) . In the Matrigel-coated Transwell invasion assay, silencing of CLIC1 inhibited the invasion of liver cancer cells (Fig. 3I) . These results demonstrated that suppression of CLIC1 functions as a metastasis inhibitor in liver cancer cells and has an effect similar to that of miR-124 in liver cancer cells.
CLIC1 overexpression reverses the miR-124-mediated inhibition of cancer cell migration and invasion.
Since CLIC1 is one of the targets of miR-124, CLIC1 was overexpressed in HepG2 cells transfected with an expression plasmid together with miR-124. As expected, miR-124 itself and miR-124 with the pEGFP-N1 vector both inhibited cell migration in the scratch wound-healing motility assay (Fig. 4A) . Similar to the miR-124 negative control, cells expressing CLIC1 and miR-124 migrated faster and had faster closure of wound healing than those transfected with miR-124 alone or miR-124 with the vehicle vector pEGFP-N1. In the Transwell assay without Matrigel coating, there were fewer cells able to migrate through the membrane in both the miR-124 and miR-124 + pEGFP-N1 vector groups, but cells expressing CLIC1 and miR-124 migrated faster than cells transfected with miR-124 or miR-124 + pEGFP-N1 vector (Fig. 4B ). Similar to cell migration, CLIC1 also reversed the miR-124-induced inhibition of liver cancer cell invasion in the Matrigel-coated Transwell invasion assay (Fig. 4C) . These results further support the hypothesis that CLIC1 is target of miR-124 and is involved in the inhibition of liver cancer cell migration and invasion.
Discussion
The goal of the present study was to investigate the role of miR-124 in hepatocarcinogenesis. miR-124 is highly expressed in the brain and was previously demonstrated to be a 'brain-enriched' miRNA (10,11). In recent years, researchers have demonstrated that the expression of miR-124 is dysregulated in almost all tumors, such as colorectal cancer (27) , gastric cancer (28), lung cancer (16) and hepatocellular carcinoma (29) . In the progression of cancer, miR-124 not only acts as a suppressor of tumor growth but also decreases cell invasion and metastasis. These previous results suggest that miR-124 plays an important role in tumorigenesis and tumor progression. The present study found that miR-124 was downregulated in liver cancer cells and that miR-124 could suppress liver cancer cell proliferation, migration and invasion, indicating its role as a tumor suppressor in liver cancer.
In an earlier study, it was shown that overexpression of miR-124 suppressed tumor growth by targeting STAT3 (30) , but the mechanism of action of miR-124 in liver cancer metastasis remained elusive. Invasion, as one of the hallmarks of malignant tumors, renders liver cancer difficult to cure. To elucidate the mechanism of metastasis, miR-124 targets were investigated using 2-DGE and mass spectrometry to analyze the differentially expressed proteins between miR-124-overexpressing and control cells. The results of the mass spectrometry led to a focus on CLIC1 as a potential target. Furthermore, the results revealed that miR-124 directly targeted CLIC1 to inhibit cell migration and invasion in liver cancer cells. Moreover, CLIC1 rescued the miR-124-mediated repression of cell migration and invasion. For the first time, to the best of our knowledge, CLIC1 was identified as a functional target of miR-124 in the inhibition of cell migration and invasion. These findings suggested that miR-124 and CLIC1 play critical roles in liver cancer metastasis.
From the 2-DGE and mass spectrometry results, several proteins with decreased expression were identified. Based on literature research, CLIC1 is highly expressed in several human malignant tumors, such as nasopharyngeal carcinoma, ovarian cancer and glioma, and was considered a promising diagnostic biomarker (31) (32) (33) . According to functional research, CLIC1 plays an important role in neoplastic transformation (34, 35) , and promotes the cell motility and invasion of gallbladder carcinoma (36) and prostate cancer (37) . However, the function of CLIC1 in liver cancer is still elusive. The present results identified CLIC1 to be a functional target of miR-124; thus, this was a focus of further investigation. A 3'-UTR luciferase assay was performed, and it was observed that co-transfection of miR-124 and the 3'-UTR of CLIC1 in the pMIR-REPORT vector resulted in decreased luciferase activity. Notably, in the 3'-UTR of CLIC1 mRNA, there was no complementary sequence of miR-124 found using the target prediction software (TargetScan). The best-known mechanism of miRNA regulation is direct binding with the seed sequence located in the 3'-UTR of the mRNA. Studies have demonstrated that miRNAs have some other regulatory methods, such as interactions with regulatory proteins, miRNAs and long noncoding RNAs to regulate protein expression. Eiring et al (38) showed that miR-328 interacts with poly(rC) binding protein 2 to modulate mRNA translation, and the interaction is independent of the miRNA seed sequence. Tang et al (39) reported that miRNA-709 regulates cell apoptosis through the miRNA-15a/16-1 pathway. miRNAs also regulate gene expression by targeting long noncoding RNAs. Du et al (40) reported that miR-124 regulates ERK/MAPK by targeting MALAT1. Altogether, these data suggest that miRNAs function in cells both through base pairing with seed sequences and though interference with other regulatory proteins, miRNAs, and long non coding RNAs. However, many miRNA regulatory mechanisms remain unknown. There may exist some unknown regulatory interaction between miR-124 and CLIC1. A future study look into the mechanism of how miR-124 regulates CLIC1 expression. CLIC1 protein expression was also markedly decreased in HepG2 cells transfected with miR-124. Subsequently, it was demonstrated that CLIC1 is a functional target of miR-124. The knockdown of CLIC1 affected cancer cell migration and invasion, but not cell proliferation. Similarly, overexpressed CLIC1 reversed the tumor suppressor function of miR-124 in terms of cell migration and invasion, but not cell viability. This suggested that the oncogenic function of CLIC1 in liver cancer cells correlates with cell motility and related pathways, but not pathways related to the cell cycle. It has been reported that CLIC1 regulates the migration and invasion of colon cancer cells by decreasing the regulatory volume decrease capacity (41) . A study by Wang et al (42) reported that the inhibition of CLIC1 channel activity leads to decreased cell migration through the ROS/ERK pathway. Further studies may be undertaken to examine the regulatory function of CLIC1 in cell motility-related signaling pathways.
In conclusion, the present study demonstrated that miR-124 is downregulated in liver cancer cells, and identified a new functional target gene of miR-124. Further in vitro studies showed that miR-124 repressed the migration and invasion of liver cancer cells by reducing the expression of CLIC1. Moreover, the knockdown of CLIC1 in miR-124 ectopically-expressing liver cancer cells reversed the effects of miR-124. Combined with all aforementioned studies, the present data contribute to the understanding of the biological function of miR-124 in tumor metastasis.
